Biogen Inc. moves from Buy to Hold: after a 20% gain, its valuation reasonably reflects growth and marginally positive Alzheimer's developments. BIIB trades above my July $223.70 DCF estimate; raising assumed growth from 2.5% to 3.5% yields $241.38, closer to its current price. Diranersen's two-year data are encouraging, but its Phase 2 trial missed its primary endpoint, and an inverse dose response complicates Phase 3.








